Although the current study reported a UTI development frequency of 13.1% in patients with diabetes treated with SGLT2 inhibitors, it is still lower than the reported national and global incidences, which can be partly explained by the smaller study population. This evidence concerns the gene SLC5A2 and diabetes mellitus.